Develops novel therapeutics for neuronal hypersensitivity disorders, advancing a first-in-class FAAH‑inhibiting proprietary small molecule for refractory chronic cough with demonstrated preclinical efficacy and favorable safety. Lead program is progressing toward first‑in‑human Phase 1/1b studies and has potential across indications including hyperactive bladder, peripheral neuropathic pain, and migraine.